Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Oncobiologics, XOMA ink collaboration
September 2012
SHARING OPTIONS:

CRANBURY, N.J.Oncobiologics Inc. and XOMA Corp. will collaborate to develop novel biotherapeutics based on engineering single-chain variable fragments (scFv). Per the agreement, Oncobiologics will make use of XOMA's ADAPT fully human antibody technology platform for its drug discovery program, and has selected clinically validated targets to be used in developing its platform targeting oncology, immuno-oncology and immunology. Oncobiologics will have access to XOMA's library of scFv antibodies and associated patent estate, and will use XOMA's software tools to advance its drug candidates. Financial details were not disclosed.

"We are very excited to partner with XOMA to advance our discovery pipeline. Their proven technology represents an important asset to support our strategy to deliver improved efficacy and safety in our drug candidates," said Dr. Pankaj Mohan, founder and CEO of Oncobiologics.


 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.